XNAS
DWTX
Market cap6mUSD
Jul 09, Last price
4.92USD
1D
1.65%
1Q
67.35%
IPO
-98.11%
Name
Dogwood Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-12m
CFO
-9m
Profile
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
Valuation
Title USD in thousands, except ratios and share amounts | FY |
|---|---|
| 2024‑12 | |
| Income | |
Revenues | |
Cost of revenue | 12,227 |
Unusual Expense (Income) | |
NOPBT | (12,227) |
NOPBT Margin | |
Operating Taxes | (503) |
Tax Rate | |
NOPAT | (12,227) |
Net income | (12,350) |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | 1,382 |
BB yield | |
| Debt | |
Debt current | 50 |
Long-term debt | 15,741 |
Deferred revenue | |
Other long-term liabilities | |
Net debt | 942 |
| Cash flow | |
Cash from operating activities | (8,791) |
CAPEX | |
Cash from investing activities | 3,762 |
Cash from financing activities | 16,704 |
FCF | |
| Balance | |
Cash | 14,848 |
Long term investments | |
Excess cash | 14,848 |
Stockholders' equity | (3,276) |
Invested Capital | 83,143 |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | |
Price | 2.49 |
Market cap | |
EV | |
EBITDA | (12,215) |
EV/EBITDA | |
Interest | 92 |
Interest/NOPBT | |